Reaction
Large Intestinal Stenosis reporting signals
As of the last recalculation, Large Intestinal Stenosis appears in 1,952 FAERS reports alongside 25 co-occurring drug terms. The strongest observed disproportionality signal is VEDOLIZUMAB (PRR 42.5).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Vedolizumab | 293 | 42.5 | 42.6 |
| Adalimumab-Fkjp | 108 | 26.3 | 26.3 |
| Adalimumab-Aaty | 110 | 26.2 | 26.3 |
| Azathioprine | 189 | 25.2 | 25.3 |
| Adalimumab-Adaz | 114 | 24.4 | 24.5 |
| Adalimumab | 868 | 22.8 | 22.8 |
| Mesalamine | 110 | 22.1 | 22.1 |
| Infliximab-Dyyb | 46 | 17.2 | 17.2 |
| Infliximab | 272 | 15.3 | 15.3 |
| Mercaptopurine | 21 | 13.0 | 13.1 |
| Ustekinumab | 118 | 13.0 | 13.0 |
| Meperidine Hydrochloride | 11 | 12.8 | 12.8 |
| Diclofenac | 85 | 11.0 | 11.0 |
| Risankizumab-Rzaa | 77 | 10.4 | 10.4 |
| Iron Sucrose | 9 | 10.1 | 10.1 |
| Cholestyramine | 11 | 9.7 | 9.8 |
| Midazolam Hydrochloride | 24 | 9.6 | 9.6 |
| Diphenoxylate Hydrochloride And Atropine Sulfate | 12 | 9.4 | 9.4 |
| Upadacitinib | 60 | 8.1 | 8.1 |
| Diclofenac Sodium | 88 | 6.5 | 6.5 |
| Teduglutide | 7 | 5.6 | 5.6 |
| Erlotinib | 4 | 4.4 | 4.4 |
| Crizotinib | 4 | 3.4 | 3.4 |
| Encorafenib | 3 | 3.2 | 3.2 |
| Diroximel Fumarate | 3 | 2.7 | 2.7 |